Monday, November 16, 2026Every story links to its original source.

Genome News

Genomics news, traced to the source.

Reading

On This Day in Genomics

Blood test detects tumor DNA with 85.0% clinical sensitivity in advanced cancer study

A blood test covering over 50 cancer-related genes showed 85.0% clinical sensitivity in a study of 165 consecutive matched blood and tissue samples from patients with stage III-IV solid tumors. Tissue sequencing showed 80.7% sensitivity. Clinical sensitivity measures how often a test detects the mutations being sought. Published in PLoS One on 16 October 2015, the study by Lanman RB and colleagues evaluated Digital Sequencing, a method for reading tumor DNA circulating in blood. The test also had a 99.8% assay success rate across 1,000 consecutive samples in clinical practice.

The method examined cell-free circulating tumor DNA, genetic material from solid tumors found in the blood. It used next-generation sequencing to read many DNA targets in parallel and examine them repeatedly within one sample. That allowed the researchers to assess a broad panel of genes from a single blood draw.

The team tested analytical sensitivity by progressively diluting known samples. The assay detected mutations down to a mutant allele fraction of 0.1%, meaning the altered version accounted for that proportion of the DNA copies being assessed. Analytical specificity, a measure of how well the test avoided false positive results, exceeded 99.9999%. The authors said this enabled coverage of many genes without the false positives typically seen with traditional sequencing assays when mutant fractions fell below 5%.

The matched samples came from five outside centers, and the clinical comparison involved patients with stage III-IV solid tumors. The authors described a role for plasma DNA testing in advanced cancer when an initial tissue biopsy was inadequate, could not be obtained for genomic testing or yielded no useful genomic information. Testing could also be used when cancer progressed despite treatment. In these settings, the authors said, blood testing could prevent repeated invasive biopsies and reduce the costs, complications and delays associated with obtaining tissue for genomic testing.

Sources

Back to today in history · Browse the archive